全关节置换术后使用Xa因子抑制剂增加出血和伤口并发症发生率
回顾性分析59例(31膝、28髋)关节置换患者,27例(46%)用阿司匹林、32例(54%)用Xa因子抑制剂预防静脉血栓栓塞(VTE)。Xa因子抑制剂组6/32例(18.7%)发生术后出血/伤口并发症,阿司匹林组0例(P=0.03);两组均无新发VTE,血红蛋白变化无显著差异(-2.76 g/dL vs -2.84 g/dL,P=0.73)。作者认为Xa因子抑制剂与更高的出血/伤口并发症发生率相关,VTE预防选择应基于出血和伤口并发症风险与VTE风险的权衡。
要点
- Xa因子抑制剂组出血/伤口并发症6/32例(18.7%),阿司匹林组0例(P=0.03)。
- 两组均无新发VTE并发症。
- 血红蛋白变化阿司匹林组-2.76 g/dL vs Xa因子抑制剂组-2.84 g/dL(P=0.73)。
核心结论
- 在作者研究的全关节置换患者中,Xa因子抑制剂与更高的出血/伤口并发症发生率相关。
- VTE预防选择应基于每位患者出血和伤口并发症风险与VTE风险的权衡。
研究设计与样本
- 回顾性综述了在高容量关节置换转诊中心连续接受关节置换的59例患者(31膝、28髋),涵盖本院实施新VTE风险分层工具前后。
- 排除有VTE病史、双侧手术或已有需VTE药物预防的医学情况的患者。
主要发现
- 27例(46%)使用阿司匹林预防VTE,32例(54%)使用Xa因子抑制剂。
- Xa因子抑制剂组6/32例(18.7%)发生术后出血/伤口并发症(4例延迟愈合/水疱,1例血肿/过度瘀斑,1例因蜂窝织炎再入院)。
- 阿司匹林组出血/伤口并发症0例(0%),与Xa因子抑制剂组比较P=0.03。
- 血红蛋白变化:阿司匹林组-2.76 g/dL vs Xa因子抑制剂组-2.84 g/dL(P=0.73)。
- 两组均无新发VTE并发症。
临床怎么用
- 作者认为VTE预防选择应基于每位患者出血和伤口并发症风险与VTE风险的权衡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Factor-Xa inhibitors have been introduced for prevention of venous thromboembolism (VTE) after joint arthroplasty. However, these agents could also be associated with bleeding or wound complications after surgery. METHODS: We retrospectively reviewed a consecutive series of 59 patients (31 knees, 28 hips) undergoing joint arthroplasty at a high-volume joint arthroplasty referral center, both before and after implementation of a new VTE risk-stratification tool at our institution. Patients with a history of VTE, bilateral procedures, or medical conditions already requiring VTE chemoprophylaxis were excluded. We reviewed the medical records to determine (1) type of VTE prophylaxis used, (2) incidence of bleeding/wound complications in the postoperative period, (3) incidence of VTE in the postoperative period, and (4) change in serum hemoglobin. RESULTS: Twenty-seven patients (46%) were given aspirin for VTE prophylaxis, while 32 patients (54%) received a factor-Xa inhibitor. There were no new VTE complications in either group. And 6 of 32 patients (18.7%) in the Xa inhibitor group had a postoperative bleeding/wound complication (4 delayed healing/blistering, 1 hematoma/excessive ecchymosis, and 1 readmission for cellulitis). There were no (0%) bleeding/wound complications in the aspirin group (P = .03). The change in hemoglobin level was -2.76 g/dL in patients receiving aspirin vs -2.84 g/dL in patients receiving a Xa inhibitor (P = .73). CONCLUSION: In our study of total joint patients, factor-Xa inhibitors were associated with a higher incidence of bleeding/wound complications. The choice of VTE prophylaxis should be based on the perceived risks of bleeding and wound complications compared to the risks of VTE in each patient.
引用
- Garfinkel JH, Gladnick BP, Roland N, et al. Increased Incidence of Bleeding and Wound Complications With Factor-Xa Inhibitors After Total Joint Arthroplasty. J Arthroplasty. 2017. PMID: 28947374. doi:10.1016/j.arth.2017.08.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。